RhumbLine Advisers
CRNX

RhumbLine Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

RhumbLine Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Buy
129,908
+11,488
+10% +$427K ﹤0.01% 1481
2026
Q1 		$4.3M Buy
118,420
+2,668
+2% +$119K ﹤0.01% 1471
2025
Q4 		$5.39M Sell
115,752
-15,770
-12% -$702K ﹤0.01% 1361
2025
Q3 		$5.48M Sell
131,522
-3,785
-3% -$121K ﹤0.01% 1382
2025
Q2 		$3.89M Buy
135,307
+3,357
+3% +$104K ﹤0.01% 1543
2025
Q1 		$4.43M Buy
131,950
+7,872
+6% +$294K ﹤0.01% 1419
2024
Q4 		$6.34M Buy
124,078
+15,359
+14% +$859K 0.01% 1305
2024
Q3 		$5.56M Sell
108,719
-3,600
-3% -$186K 0.01% 1374
2024
Q2 		$5.03M Buy
112,319
+3,626
+3% +$167K ﹤0.01% 1395
2024
Q1 		$5.09M Buy
108,693
+1,478
+1% +$57.8K ﹤0.01% 1411
2023
Q4 		$3.81M Buy
107,215
+661
+0.6% +$20.3K ﹤0.01% 1574
2023
Q3 		$3.17M Buy
106,554
+16,400
+18% +$338K ﹤0.01% 1606
2023
Q2 		$1.62M Buy
90,154
+8,250
+10% +$165K ﹤0.01% 2021
2023
Q1 		$1.31M Buy
81,904
+2,916
+4% +$54K ﹤0.01% 2011
2022
Q4 		$1.45M Sell
78,988
-7
-0% -$123 ﹤0.01% 1948
2022
Q3 		$1.55M Buy
78,995
+5,439
+7% +$111K ﹤0.01% 1902
2022
Q2 		$1.37M Buy
73,556
+25,855
+54% +$516K ﹤0.01% 1965
2022
Q1 		$1.05M Buy
47,701
+4,654
+11% +$94.2K ﹤0.01% 2113
2021
Q4 		$1.22M Buy
43,047
+7,644
+22% +$188K ﹤0.01% 2125
2021
Q3 		$745K Buy
35,403
+1,852
+6% +$38.7K ﹤0.01% 2362
2021
Q2 		$632K Buy
33,551
+5,154
+18% +$90.6K ﹤0.01% 2449
2021
Q1 		$434K Sell
28,397
-2,370
-8% -$36.7K ﹤0.01% 2556
2020
Q4 		$434K Buy
30,767
+2,780
+10% +$38.7K ﹤0.01% 2495
2020
Q3 		$439K Sell
27,987
-4,670
-14% -$71.4K ﹤0.01% 2345
2020
Q2 		$572K Buy
32,657
+19,959
+157% +$340K ﹤0.01% 2280
2020
Q1 		$187K Hold
12,698
– – ﹤0.01% 2612
2019
Q4 		$319K Buy
12,698
+72
+0.6% +$1.37K ﹤0.01% 2562
2019
Q3 		$190K Sell
12,626
-125
-1% -$2.43K ﹤0.01% 2761
2019
Q2 		$319K Buy
12,751
+2,975
+30% +$73.7K ﹤0.01% 2577
2019
Q1 		$223K Buy
9,776
+1,301
+15% +$32K ﹤0.01% 2705
2018
Q4 		$254K Buy
+8,475
New +$239K ﹤0.01% 2617

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's CRNX Position: Q2 2026 in Review

RhumbLine Advisers increased its Crinetics Pharmaceuticals (CRNX) stake by 9.7% in Q2 2026, buying an estimated $427K and bringing the position to 129,908 shares worth $4.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

RhumbLine Advisers first reported a position in CRNX in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.34M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • RhumbLine Advisers held 129,908 shares of Crinetics Pharmaceuticals worth $4.86M as of Q2 2026.
  • RhumbLine Advisers bought 11,488 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $427K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1481 holding.
  • RhumbLine Advisers first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • RhumbLine Advisers's Crinetics Pharmaceuticals position peaked at $6.34M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.